![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
News
Chugai and Two Cells Co Ltd Announce a Licensing agreement for “gMSC®1,” a Regenerative Cellular Medicine for Chondrogenesis in the Knee
Chugai Pharma and TWO CELLS Co Ltd announced that on April 25, 2016, both companies concluded a licensing agreement regarding gMSC®1, a regenerative cellular...
Drug Research
Nplate Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia
Amgen announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate in children with symptomatic immune thrombocytopenia. ...
News
New Data Reaffirm Positive Benefit-Risk Balance of Bayer’s Xarelto® in Patients with Atrial Fibrillation in Daily Clinical Practice
Bayer AG and its development partner Janssen Pharmaceuticals, Inc announced results from a new real-world study, REVISIT-US. In REVISIT-US reduced rates...
Press Releases
Kanuma receives marketing approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals, Inc announced that Japan’s Ministry of Health, Labour and Welfare has approved Kanuma for the treatment of patients of all ages in...
Press Releases
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors
Novartis announced that the United States FDA approved Afinitor® tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal...
Press Releases
Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug
Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate,...
Press Releases
U.S. FDA Accepts Filing Of Cardiovascular Outcomes Data For Jardiance® (Empagliflozin)
The U.S. FDA accepted a supplemental New Drug Application for Jardiance based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
